参考文献[1]
SwinnenJV, BrusselmansK, VerhoevenG. Increased lipogenesis in cancer cells：new players，novel targets[J]. Curr Opin Clin Nutr Metab Care，2006，9(4):358-365. .
[2]
PosticC, GirardJ. The role of the lipogenic pathway in the development of hepatic steatosis[J]. Diabetes Metab，2008，34(6Pt 2):643-648. .
[3]
NtambiJM. The regulation of stearoyl-CoA desaturase（SCD）[J]. Prog Lipid Res，1995，34(2):139-150.
[4]
Neuschwander-TetriBA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis：the central role of nontriglyceride fatty acid metabolites[J]. Hepatology，2010，52(2):774-788. .
[5]
KuhajdaFP. Fatty-acid synthase and human cancer：new perspectives on its role in tumor biology[J]. Nutrition，2000，16(3):202-208.
[6]
WangY, KuhajdaFP, LiJN，et al. Fatty acid synthase（FAS）expression in human breast cancer cell culture supernatants and in breast cancer patients[J]. Cancer Lett，2001，167(1):99-104.
[7]
NotarnicolaM, AltomareDF, CalvaniM，et al. Fatty acid synthase hyperactivation in human colorectal cancer：relationship with tumor side and sex[J]. Oncology，2006，71(5-6):327-332. .
[8]
CruzMD, WaliRK, BianchiLK，et al. Colonic mucosal fatty acid synthase as an early biomarker for colorectal neoplasia：modulation by obesity and gender[J]. Cancer Epidemiol Biomarkers Prev，2014，23(11):2413-2421. .
[9]
NotarnicolaM, TutinoV, CalvaniM，et al. Serum levels of fatty acid synthase in colorectal cancer patients are associated with tumor stage[J]. J Gastrointest Cancer，2012，43(3):508-511. .
[10]
LamCW, LawCY. Untargeted mass spectrometry-based metabolomic profiling of pleural effusions：fatty acids as novel cancer biomarkers for malignant pleural effusions[J]. J Proteome Res，2014，13(9):4040-4046. .
[11]
VeigelD, WagnerR, StübigerG，et al. Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells[J]. Int J Cancer，2015，136(9):2078-2090. .
[12]
WalterK, HongSM, NyhanS，et al. Serum fatty acid synthase as a marker of pancreatic neoplasia[J]. Cancer Epidemiol Biomarkers Prev，2009，18(9):2380-2385. .
[13]
ChavarroJE, KenfieldSA, StampferMJ，et al. Blood levels of saturated and monounsaturated fatty acids as markers of de novo lipogenesis and risk of prostate cancer[J]. Am J Epidemiol，2013，178(8):1246-1255. .
[14]
MigitaT, RuizS, FornariA，et al. Fatty acid synthase：a metabolic enzyme and candidate oncogene in prostate cancer[J]. J Natl Cancer Inst，2009，101(7):519-532. .
[15]
HeemersH, MaesB, FoufelleF，et al. Androgens stimulate lipogenic gene expression in prostate cancer cells by activation of the sterol regulatory element-binding protein cleavage activating protein/sterol regulatory element-binding protein pathway[J]. Mol Endocrinol，2001，15(10):1817-1828. .
[16]
Van de SandeT, De SchrijverE, HeynsW，et al. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells[J]. Cancer Res，2002，62(3):642-646.
[17]
GranerE, TangD, RossiS，et al. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer[J]. Cancer Cell，2004，5(3):253-261.
[18]
SelvendiranK, AhmedS, DaytonA，et al. HO-3867，a synthetic compound，inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase[J]. Mol Cancer Res，2010，8(9):1188-1197. .
[19]
MenendezJA, VellonL, MehmiI，et al. Inhibition of fatty acid synthase（FAS）suppresses HER2/neu（erbB-2）oncogene overexpression in cancer cells[J]. Proc Natl Acad Sci U S A，2004，101(29):10715-10720. .
[20]
HartkopfAD, BanysM, FehmT. HER2-positive DTCs/CTCs in breast cancer[J]. Recent Results Cancer Res，2012，195:203-215. .
[21]
LeeJS, YoonIS, LeeMS，et al. Anticancer activity of pristimerin in epidermal growth factor receptor 2-positive SKBR3 human breast cancer cells[J]. Biol Pharm Bull，2013，36(2):316-325.
[22]
Kumar-SinhaC, IgnatoskiKW, LippmanME，et al. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis[J]. Cancer Res，2003，63(1):132-139.
[23]
HuJ, CheL, LiL，et al. Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice[J]. Sci Rep，2016，6:20484. .
[24]
DasguptaS, PutluriN, LongW，et al. Coactivator SRC-2-dependent metabolic reprogramming mediates prostate cancer survival and metastasis[J]. J Clin Invest，2015，125(3):1174-1188. .
[25]
BianY, YuY, WangS，et al. Up-regulation of fatty acid synthase induced by EGFR/ERK activation promotes tumor growth in pancreatic cancer[J]. Biochem Biophys Res Commun，2015，463(4):612-617. .
[26]
QiuZ, HuangC, SunJ，et al. RNA interference-mediated signal transducers and activators of transcription 3 gene silencing inhibits invasion and metastasis of human pancreatic cancer cells[J]. Cancer Sci，2007，98(7):1099-1106. .
[27]
CarvalhoMA, ZecchinKG, SeguinF，et al. Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model[J]. Int J Cancer，2008，123(11):2557-2565. .
[28]
ChajèsV, ThiébautAC, RotivalM，et al. Association between serum trans-monounsaturated fatty acids and breast cancer risk in the E3N-EPIC study[J]. Am J Epidemiol，2008，167(11):1312-1320. .
[29]
MauvoisinD, CharfiC, LounisAM，et al. Decreasing stearoyl-CoA desaturase-1 expression inhibits β-catenin signaling in breast cancer cells[J]. Cancer Sci，2013，104(1):36-42. .
[30]
LinSY, XiaW, WangJC，et al. Beta-catenin，a novel prognostic marker for breast cancer：its roles in cyclin D1 expression and cancer progression[J]. Proc Natl Acad Sci U S A，2000，97(8):4262-4266. .
[31]
ScagliaN, ChisholmJW, IgalRA. Inhibition of stearoylCoA desaturase-1 inactivates acetyl-CoA carboxylase and impairs proliferation in cancer cells：role of AMPK[J]. PLoS One，2009，4(8):e6812. .
[32]
HadadSM, FlemingS, ThompsonAM. Targeting AMPK：a new therapeutic opportunity in breast cancer[J]. Crit Rev Oncol Hematol，2008，67(1):1-7. .
[33]
Rios-EstevesJ, ReshMD. Stearoyl CoA desaturase is required to produce active，lipid-modified Wnt proteins[J]. Cell Rep，2013，4(6):1072-1081. .
[34]
ScagliaN, IgalRA. Inhibition of stearoyl-CoA desaturase 1 expression in human lung adenocarcinoma cells impairs tumorigenesis[J]. Int J Oncol，2008，33(4):839-850.
[35]
HuangGM, JiangQH, CaiC，et al. SCD1 negatively regulates autophagy-induced cell death in human hepatocellular carcinoma through inactivation of the AMPK signaling pathway[J]. Cancer Lett，2015，358(2):180-190. .
[36]
KimSJ, ChoiH, ParkSS，et al. Stearoyl CoA desaturase（SCD）facilitates proliferation of prostate cancer cells through enhancement of androgen receptor transactivation[J]. Mol Cells，2011，31(4):371-377. .
[37]
KhanA, AljarbouAN, AldebasiYH，et al. Resveratrol suppresses the proliferation of breast cancer cells by inhibiting fatty acid synthase signaling pathway[J]. Cancer Epidemiol，2014，38(6):765-772. .
[38]
BlancafortA, Giró-PerafitaA, OliverasG，et al. Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs[J]. PLoS One，2015，10(6):e0131241. .
[39]
PatelAV, JohanssonG, ColbertMC，et al. Fatty acid synthase is a metabolic oncogene targetable in malignant peripheral nerve sheath tumors[J]. Neuro Oncol，2015，17(12):1599-1608. .
[40]
WenS, NiuY, LeeSO，et al. Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells[J]. Mol Carcinog，2016. .
[41]
WayTD, TsaiSJ, WangCM，et al. Chemical constituents of Rhododendron formosanum show pronounced growth inhibitory effect on non-small-cell lung carcinoma cells[J]. J Agric Food Chem，2014，62(4):875-884. .
[42]
AgostiniM, AlmeidaLY, BastosDC，et al. The fatty acid synthase inhibitor orlistat reduces the growth and metastasis of orthotopic tongue oral squamous cell carcinomas[J]. Mol Cancer Ther，2014，13(3):585-595. .
[43]
RoongtaUV, PabalanJG, WangX，et al. Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy[J]. Mol Cancer Res，2011，9(11):1551-1561. .
[44]
FlavenyCA, GriffettK, El-GendyBel-D，et al. Broad anti-tumor activity of a small molecule that selectively targets the Warburg effect and lipogenesis[J]. Cancer Cell，2015，28(1):42-56. .
[45]
MahtaniR, KhanR, JahanzebM. The potential application of zoledronic acid as anticancer therapy in patients with non-small-cell lung cancer[J]. Clin Lung Cancer，2011，12(1):26-32. .
[46]
McKayRR, LinX, AlbigesL，et al. Statins and survival outcomes in patients with metastatic renal cell carcinoma[J]. Eur J Cancer，2016，52:155-162. .
